Existing problems of prevention and treatment of chemo-induced peripheral neuropathy: world experience and own data

Author:

Chizh G.  А.1ORCID,Rykov I.  V.2ORCID,Orlova D.  S.3,Kuzin S.  О.3ORCID,Elmurzaev А. В.3ORCID,Shishkin А. В.3ORCID,Bogomolov V. V.3

Affiliation:

1. Saint Petersburg Clinical Hospital; Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia

2. Saint Petersburg Clinical Hospital; V. A. Almazov National Medical Research Centre, Ministry of Health of Russia

3. Saint Petersburg Clinical Hospital

Abstract

Chemotherapy-related peripheral neuropathy (CIPN) is a complication which occurs in the most cancer patients receiving taxanes and platinum-based systemic therapy. CIPN includes the wide range of clinical symptoms, and the peripheral sensitive disorders are the most common. Some patients have CIPN-related symptoms persistent after chemotherapy completion. Impact on patient's quality of life and high prevalence among cancer patients make an active search for new ways of CIPN medical correction relevant. We reviewed the existing data on medical prophylaxis and treatment of CIPN and also presented our observation data with CIPN patients. Based on our research results, we showed that the impact of CIPN on a patient's quality's life was spread beyond the peripheral sensitivity disorder. This should be taken into account for further studying of the possible correction of CIPN.

Publisher

Russian Society of Clinical Oncology

Reference40 articles.

1. William J.G., Meena S.M., Jame A., et al. NCCN Guidelines insights: breast cancer, version 4.2023. J Natl Compr Canc Netw 2023;21(6):594–608. https://doi.org/10.6004/jnccn.2023.0031

2. Ettinger D.S., Wood D.E., Aisner D.L., et al. Non-Small Cell Lung Cancer. NCCN Guidelines Version 3.2023. J Natl Compr Canc Netw 2023;21(4):340–350. https://doi.org/10.6004/jnccn.2023.0020

3. NCCN Guidelines, Version 3.2023. Small Cell Lung Cancer. Available at: https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1&id=1462

4. NCCN Guidelines, Version 2.2023. Colon Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf

5. NCCN Guidelines, Version 2.2023. Prostate Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3